Digital analysis of distant and cancer-associated mammary adipocytes.


Journal

Breast (Edinburgh, Scotland)
ISSN: 1532-3080
Titre abrégé: Breast
Pays: Netherlands
ID NLM: 9213011

Informations de publication

Date de publication:
Dec 2020
Historique:
received: 10 08 2020
revised: 04 10 2020
accepted: 13 10 2020
pubmed: 30 10 2020
medline: 12 8 2021
entrez: 29 10 2020
Statut: ppublish

Résumé

Adipocytes and cancer-associated adipocytes (CAAs) are poorly investigated cells in the tumor microenvironment. Different image analysis software exist for identifying and measuring these cells using scanned hematoxylin and eosin (H&E)-stained slides. It is however unclear which one is the most appropriate for breast cancer (BC) samples. Here, we compared three software (AdipoCount, Adiposoft, and HALO®). HALO® outperformed the other methods with regard to adipocyte identification, (> 96% sensitivity and specificity). All software performed equally good with regard to area and diameter measurement (concordance correlation coefficients > 0.97 and > 0.96, respectively). We then analyzed a series of 10 BCE samples (n = 51 H&E slides) with HALO®. Distant adipocytes were defined >2 mm away from cancer cells or fibrotic region, whereas CAAs as the first three lines of adipocytes close to the invasive front. Intra-mammary heterogeneity was limited, implying that measuring a single region of ∼500 adipocytes provides a reliable estimation of the distribution of their size features. CAAs had smaller areas (median fold-change: 2.62) and diameters (median fold-change: 1.64) as compared to distant adipocytes in the same breast (both p = 0.002). The size of CAAs and distant adipocytes was associated with the body mass index (BMI) of the patient (area: rho = 0.89, p = 0.001; rho = 0.71, p = 0.027, diameter: rho = 0.87 p = 0.002; rho = 0.65 p = 0.049, respectively). To conclude, we demonstrate that quantifying adipocytes in BC sections is feasible by digital pathology using H&E sections, setting the basis for a standardized analysis of mammary adiposity in larger series of patients.

Identifiants

pubmed: 33120083
pii: S0960-9776(20)30195-8
doi: 10.1016/j.breast.2020.10.004
pmc: PMC7589564
pii:
doi:

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

179-186

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare no conflict of interest.

Références

Ann Endocrinol (Paris). 2013 May;74(2):108-10
pubmed: 23566616
Breast Cancer Res. 2019 Jan 17;21(1):7
pubmed: 30654824
Cancer Metab. 2017 Jan 13;5:1
pubmed: 28101337
Front Physiol. 2018 Feb 20;9:85
pubmed: 29515452
J Clin Oncol. 2016 Dec 10;34(35):4203-4216
pubmed: 27903149
Ann Anat. 2002 Mar;184(2):181-4
pubmed: 11936199
J Lipid Res. 2012 Dec;53(12):2791-6
pubmed: 22993232
J Lipid Res. 2020 Feb;61(2):205-218
pubmed: 31806729
PLoS Comput Biol. 2009 Mar;5(3):e1000324
pubmed: 19325873
Cell Metab. 2020 Jun 2;31(6):1154-1172.e9
pubmed: 32492394
Nat Rev Endocrinol. 2019 Mar;15(3):139-154
pubmed: 30459447
Ann Oncol. 2014 Oct;25(10):1901-1914
pubmed: 24769692
N Engl J Med. 2019 Dec 19;381(25):2440-2450
pubmed: 31851800
NPJ Breast Cancer. 2017 May 3;3:19
pubmed: 28649659
Cancer Prev Res (Phila). 2015 May;8(5):349-58
pubmed: 25720743
Oncotarget. 2017 May 20;8(34):57622-57641
pubmed: 28915700
JAMA Oncol. 2015 Aug;1(5):611-21
pubmed: 26182172
Sci Rep. 2017 Dec 4;7(1):16878
pubmed: 29203879
Lancet. 2016 Apr 2;387(10026):1377-1396
pubmed: 27115820
Cancer Prev Res (Phila). 2017 Apr;10(4):235-243
pubmed: 28270386
J Hematol Oncol. 2019 Sep 10;12(1):95
pubmed: 31500658
Mol Cancer Res. 2017 Dec;15(12):1704-1713
pubmed: 29117945
Cancer Prev Res (Phila). 2011 Jul;4(7):1021-9
pubmed: 21622727
Adv Ther. 2020 Jun;37(6):2734-2747
pubmed: 32410166
Int J Cancer. 2016 Sep 1;139(5):1140-9
pubmed: 27116366
J Biomed Sci. 2018 Dec 3;25(1):89
pubmed: 30509250
Compr Physiol. 2017 Dec 12;8(1):237-282
pubmed: 29357128
Cancer Res. 2011 Apr 1;71(7):2455-65
pubmed: 21459803
Nature. 2008 Jun 5;453(7196):783-7
pubmed: 18454136
Cells. 2019 Aug 08;8(8):
pubmed: 31398937
Porto Biomed J. 2017 Nov-Dec;2(6):333-339
pubmed: 32258790
J Clin Invest. 2019 Jul 2;129(8):3006-3017
pubmed: 31264969

Auteurs

Edoardo Isnaldi (E)

KU Leuven, Department of Oncology, Laboratory for Translational Breast Cancer Research, B-3000, Leuven, Belgium; Department of Internal Medicine and Medical Specialties, University of Genoa, IT-16132, Genoa, Italy.

François Richard (F)

KU Leuven, Department of Oncology, Laboratory for Translational Breast Cancer Research, B-3000, Leuven, Belgium.

Maxim De Schepper (M)

KU Leuven, Department of Oncology, Laboratory for Translational Breast Cancer Research, B-3000, Leuven, Belgium.

Delphine Vincent (D)

Université Libre de Bruxelles, Institut Jules Bordet, J.C. Heuson Breast Cancer Translational Research Laboratory, B-1000, Brussels, Belgium.

Sophia Leduc (S)

KU Leuven, Department of Oncology, Laboratory for Translational Breast Cancer Research, B-3000, Leuven, Belgium.

Marion Maetens (M)

KU Leuven, Department of Oncology, Laboratory for Translational Breast Cancer Research, B-3000, Leuven, Belgium.

Tatjana Geukens (T)

KU Leuven, Department of Oncology, Laboratory for Translational Breast Cancer Research, B-3000, Leuven, Belgium.

Giuseppe Floris (G)

KU Leuven, Translational Cell and Tissue Research Unit, Department of Imaging and Pathology, B-3000, Leuven, Belgium; University Hospitals Leuven, Department of Pathology, B-3000, Leuven, Belgium.

Ghizlane Rouas (G)

Université Libre de Bruxelles, Institut Jules Bordet, J.C. Heuson Breast Cancer Translational Research Laboratory, B-1000, Brussels, Belgium.

Fatima Cardoso (F)

Champalimaud Clinical Center-Champalimaud Foundation, Breast Unit, P-1400-038, Lisbon, Portugal.

Christos Sotiriou (C)

Université Libre de Bruxelles, Institut Jules Bordet, J.C. Heuson Breast Cancer Translational Research Laboratory, B-1000, Brussels, Belgium.

Gabriele Zoppoli (G)

Department of Internal Medicine and Medical Specialties, University of Genoa, IT-16132, Genoa, Italy; Ospedale Policlinico San Martino IRCCS per L'Oncologia, IT-16132, Genoa, Italy.

Denis Larsimont (D)

Université Libre de Bruxelles, Institut Jules Bordet, Pathology Department, B-1000, Brussels, Belgium.

Elia Biganzoli (E)

Unit of Medical Statistics, Biometry and Bioinformatics "Giulio A. Maccacaro", Department of Clinical Sciences and Community Health & DSRC, University of Milan, Campus Cascina Rosa, Fondazione IRCCS Istituto Nazionale Tumori, IT-20133, Milan, Italy.

Christine Desmedt (C)

KU Leuven, Department of Oncology, Laboratory for Translational Breast Cancer Research, B-3000, Leuven, Belgium. Electronic address: christine.desmedt@kuleuven.be.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH